Frost & Sullivan Technology Innovation Award Conferred on AQTIS Medical BV for its Pioneering Ellanse(TM)

By Frost Sullivan, PRNE
Tuesday, February 8, 2011

LONDON, February 9, 2011 - The 2011 Frost & Sullivan European Technology Innovation of the Year
Award in Dermal Fillers is presented to AQTIS Medical BV in recognition of
its pioneering Ellanse(TM).


"This novel range of dermal fillers supports safe and cost-effective
treatments in aesthetic medicine and surgery, through immediate and sustained
performance, tuneable longevity and total bioresorbability (STAT
Technology(TM))," notes Frost & Sullivan Research Analyst Arjunvasan
Ambigapathy. "Aesthetic surgeons have observed positive results from the use
of Ellanse(TM), recommending it for most cosmetic applications."

Ellanse(TM) comes in four variants (S, M, L, and E) based on the polymer
chain strength of poly-caprolactone (PCL), with the duration of action
varying from 9 months up to 4 years. PCL, a primary component of Ellanse(TM),
is in the form of smooth microspheres, suspended homogenously in a tailored
carboxy-methylcellulose (CMC) gel-carrier and offers optimum viscosity,
desired elasticity and uniform homogeneity.

Ellanse(TM) has been designed to suit a wide range of customer needs -
based on the desired duration of action, clients can choose the appropriate
Ellanse(TM) variant. This enables its use across a wide spectrum of treatment

"Unlike hyaluronic acid (HA) fillers, Ellanse(TM) offers superior
bioresorption, coupled with maximum safety," states Ambigapathy. "Moreover,
it delivers results that last twice as long as other leading fillers due to
the fact that Ellanse(TM) acts as a biostimulator, helping patients generate
their own new collagen (neocollagenesis). Importantly, during the final
stages of bioresorption, the PCL microparticles lose mass and are completely
resorbed by intracellular phagocytosis and excreted readily through the
metabolic pathway."

Ellanse(TM) is indicated for a wide array of cosmetic (aesthetic)
treatments, which include typical cosmetic thorns like volume-depleted areas
and for soft tissue filling around nasolabial folds and marionette lines. The
product is also widely used to enhance the zygomatic arch as well as soften
wrinkles around the forehead and glabella.

The S, M, L and E strengths of Ellanse(TM) can be used to treat deep and
profound wrinkles. In addition, they can be used to treat intense volumising
issues such as lipoatrophy and cosmetic reconstructive surgery, and can also
be deployed for hand treatment.

The Technology Innovation Award is presented to the company that has
excelled in the following criteria: uniqueness of technology, impact on
functionality, impact on customer value and relevance of innovation to

Frost & Sullivan Best Practices Awards recognise companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts
compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify
best practices in the industry.

About AQTIS Medical BV

AQTIS Medical BV, the Netherlands is a privately held, medical device
company specializing in research & development, manufacturing and
commercialisation of innovative injectable medical devices. Ellanse(TM)
dermal filler developed by AQTIS Medical embeds proprietary STAT Technology
that consists of a unique set of bioresorbable medical polymer and gel
formulations. AQTIS Medical has a distinctive competence in the modification
and functionalization of bioresorbable polymers and gels in relation to
longevity and other desired performance specifications. Ellanse(TM) is
currently CE approved and used widely in most regions worldwide; In North
America FDA approval is expected by the end of 2012.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages 50 years of experience in partnering
with Global 1000 companies, emerging businesses and the investment community
from more than 40 offices on six continents. To join our Growth Partnership,
please visit

    Emily Bailey
    Promotions Coordinator
    Best Practices
    Frost & Sullivan
    P: +44-(0)20-7915-7869
    F: +44-(0)20-7730-3343

Emily Bailey, Promotions Coordinator, Best Practices, Frost & Sullivan, +44(0)20-7915-7869, Fax: +44(0)20-7730-3343, emily.bailey at

will not be displayed